Messner H A, Curtis J E, Minden M D, Tritchler D, Lockwood G, Takahashi T, Lepine J, Jamal N, Tweeddale M, Wandl U
Ontario Cancer Institute, University of Toronto, Canada.
Blood. 1987 Nov;70(5):1425-32.
Multilineage and single-lineage hemopoietic precursors were studied in 102 bone marrow transplant recipients and their respective donors to determine their contribution to clinical outcome as measured by time to engraftment and survival. The patient population was heterogenous with respect to diagnosis and disease status. They included individuals with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), aplastic anemia, and a few other hematopoietic malignancies. The frequency of various clonogenic precursors in the normal donor population varied considerably. The data yielded a symmetrical distribution. In contrast, most bone marrow transplant recipients presented with significantly reduced numbers of clonogenic cells before transplantation, resulting in skewed distribution profiles. Serial studies of recipients demonstrated a significantly lower than normal level of clonogenic precursors even 3 and 4 years after transplantation. The median values and distribution profiles approximated those observed before transplantation but did not return to measurements obtained for normal donors. Patients with ALL deviated from this pattern. The median values and distribution profiles of clonogenic precursors before transplantation approximated the pattern of normal donors. The frequency of clonogenic progenitors after transplantation, however, remained significantly lower than that of their respective donor or pretransplant values. Cell cycle studies performed after normalization of peripheral blood hematopoietic parameters demonstrated for most recipients that a higher than normal proportion of multipotent cells was in S-phase (P = .011). By univariate and multivariate approaches, clonogenic precursors and clinical parameters were assessed for their contributions to clinical outcome as measured by time to engraftment and survival time. The number of nucleated cells in the transplant inoculum contributed to survival independent of other risk factors. Patients with a higher cell load had a higher probability of surviving than did patients with a lower cell concentration in the transplant inoculum (P = .042). The frequency of clonogenic precursors in the transplant inoculum altered neither survival nor time to engraftment. The time to engraftment was significantly influenced by the frequency of clonogenic megakaryocyte precursors (CFU-M) observed in recipients prior to transplantation (P = .003). Patients with high values engrafted faster than did patients with a low frequency of CFU-M. This was independent of both diagnosis and disease status of the patients at time of transplantation.
在102名骨髓移植受者及其各自的供者中研究了多谱系和单谱系造血前体细胞,以确定它们对以植入时间和生存率衡量的临床结局的贡献。患者群体在诊断和疾病状态方面具有异质性。他们包括急性髓系白血病(AML)、慢性髓系白血病(CML)、急性淋巴细胞白血病(ALL)、再生障碍性贫血以及其他一些造血系统恶性肿瘤患者。正常供者群体中各种克隆形成前体细胞的频率差异很大。数据呈现出对称分布。相比之下,大多数骨髓移植受者在移植前克隆形成细胞数量显著减少,导致分布曲线倾斜。对受者的系列研究表明,即使在移植后3年和4年,克隆形成前体细胞水平仍显著低于正常水平。中位数和分布曲线接近移植前观察到的情况,但未恢复到正常供者的测量值。ALL患者偏离了这种模式。移植前克隆形成前体细胞的中位数和分布曲线接近正常供者的模式。然而,移植后克隆形成祖细胞的频率仍显著低于其各自供者或移植前的值。在外周血造血参数标准化后进行的细胞周期研究表明,对于大多数受者来说,处于S期的多能细胞比例高于正常水平(P = 0.011)。通过单变量和多变量方法,评估了克隆形成前体细胞和临床参数对以植入时间和生存时间衡量的临床结局的贡献。移植接种物中有核细胞的数量对生存有贡献,且独立于其他风险因素。移植接种物中细胞负荷较高的患者比细胞浓度较低的患者存活概率更高(P = 0.042)。移植接种物中克隆形成前体细胞的频率既不影响生存也不影响植入时间。植入时间受到移植前受者中观察到的克隆形成巨核细胞前体细胞(CFU-M)频率的显著影响(P = 0.003)。CFU-M值高的患者比CFU-M频率低的患者植入更快。这与移植时患者的诊断和疾病状态均无关。